UNIVERSITY COMPOUNDING PHARMACY (UCP) acquired by FAGRON
Context
Fagron acquired 100% of University Compounding Pharmacy for an Enterprise granting to Fagron a stronghold in California (a high-barrier market) and adds complementary therapeutic expertise (Urology) to its existing US portfolio (which includes Anazao). Fagron expects to realize significant synergies over the next 18-24 months by integrating UCP into its national platform.
UNIVERSITY COMPOUNDING PHARMACY (UCP), which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Based in San Diego, UCP is a specialized 503A compounding pharmacy. Unlike 503B facilities (which manufacture in bulk for hospitals), 503A pharmacies prepare patient-specific medications prescribed by doctors. UCP has built a strong niche in the "Health & Wellness" segment, with specific leadership in Urology (e.g., erectile dysfunction treatments) and Hormone Replacement Therapy (HRT). It operates in California, a state with notoriously strict pharmacy regulations, making its license and clean compliance record a valuable asset. The company generates annual revenues of around $25 million.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2026 | CIMG | DAREN TECHNOLOGY | CHINA | R&D Biotech |
| 02/2026 | IMA GROUP | PROSYS | IRELAND | Medical Devices |
| 01/2026 | ARDIAN | IVB Wellness Lab | SPAIN | Nutrition & Dietary Supplements |
| 01/2026 | YOTTA CAPITAL | VILLARD | FRANCE | Medical Consumables |
| 12/2025 | MONTAGU PRIVATE EQUITY / Kohlberg | Teleflex Medical OEM | UNITED STATES | Medical Consumables |
| 12/2025 | CHARTERHOUSE | WINBACK | FRANCE | Medical Devices |
| 11/2025 | ANJAC BEAUTY & HEALTH | HEALTH CHAIN GROUP (HCG) | SLOVENIA | CDMO |
| 11/2025 | PFIZER | METSERA | UNITED STATES | R&D Biotech |
| 11/2025 | ARLANE | DESSINTEY | FRANCE | Medical Devices |
| 10/2025 | PUBLIC MARKETS (IPO) | OTTOBOCK | GERMANY | Implants & Prosthetics |
REFERENCES
Valuation range: EV 20M - 50M USD
Revenue range: 10M - 30M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of UNIVERSITY COMPOUNDING PHARMACY (UCP) by FAGRON are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.